CA3170503A1 - Stat degraders and uses thereof - Google Patents

Stat degraders and uses thereof Download PDF

Info

Publication number
CA3170503A1
CA3170503A1 CA3170503A CA3170503A CA3170503A1 CA 3170503 A1 CA3170503 A1 CA 3170503A1 CA 3170503 A CA3170503 A CA 3170503A CA 3170503 A CA3170503 A CA 3170503A CA 3170503 A1 CA3170503 A1 CA 3170503A1
Authority
CA
Canada
Prior art keywords
ring
nitrogen
sulfur
oxygen
partially unsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3170503A
Other languages
English (en)
French (fr)
Inventor
Nan JI
Bin Yang
Xiaozhang Zheng
Xiao Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymera Therapeutics Inc
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of CA3170503A1 publication Critical patent/CA3170503A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3170503A 2020-03-17 2021-03-17 Stat degraders and uses thereof Pending CA3170503A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062990555P 2020-03-17 2020-03-17
US62/990,555 2020-03-17
US202063088945P 2020-10-07 2020-10-07
US63/088,945 2020-10-07
US202063123335P 2020-12-09 2020-12-09
US63/123,335 2020-12-09
US202163159102P 2021-03-10 2021-03-10
US63/159,102 2021-03-10
PCT/US2021/022794 WO2021188696A1 (en) 2020-03-17 2021-03-17 Stat degraders and uses thereof

Publications (1)

Publication Number Publication Date
CA3170503A1 true CA3170503A1 (en) 2021-09-23

Family

ID=77771311

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3170503A Pending CA3170503A1 (en) 2020-03-17 2021-03-17 Stat degraders and uses thereof

Country Status (9)

Country Link
US (1) US20240016942A1 (https=)
EP (1) EP4121055A4 (https=)
JP (1) JP2023518422A (https=)
CN (1) CN115776891A (https=)
AU (1) AU2021238333A1 (https=)
CA (1) CA3170503A1 (https=)
IL (1) IL296334A (https=)
MX (1) MX2022011437A (https=)
WO (1) WO2021188696A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570679B2 (en) 2019-03-29 2026-03-10 Regents Of The University Of Michigan STAT3 protein degraders
CN120574283A (zh) 2019-04-05 2025-09-02 凯麦拉医疗公司 Stat降解剂和其用途
CN115677831B (zh) * 2021-07-22 2026-03-17 杭州和正医药有限公司 拟肽类stat降解药物、组合物及应用
CA3239730A1 (en) * 2021-12-11 2023-06-15 Christopher De Savi Stat3 degraders and uses thereof
CA3253876A1 (en) * 2022-03-31 2023-10-05 Recludix Pharma, Inc. STAT MODULATORS AND THEIR USES
WO2024030628A1 (en) * 2022-08-05 2024-02-08 Kymera Therapeutics, Inc. Deuterated stat3 degraders and uses thereof
WO2024173291A1 (en) * 2023-02-13 2024-08-22 Regents Of The University Of Michigan Compounds and compositions as stat3 degraders and uses thereof
WO2024173298A1 (en) * 2023-02-13 2024-08-22 Regents Of The University Of Michigan Compounds and compositions as stat3 degraders and uses thereof
EP4709370A2 (en) * 2023-05-09 2026-03-18 Recludix Pharma, Inc. Stat degraders and uses thereof
WO2024238603A2 (en) * 2023-05-15 2024-11-21 Recludix Pharma, Inc. Stat degraders and uses thereof
EP4731622A1 (en) * 2023-06-20 2026-04-29 Regents of the University of Michigan Compounds and compositions as vhl ligands and stat3 degraders uses thereof
CN117024254B (zh) * 2023-08-10 2025-09-09 浙江大学衢州研究院 一种多氟苯酚的合成方法
WO2026007994A1 (zh) * 2024-07-03 2026-01-08 正大天晴药业集团股份有限公司 膦酸化合物及其用途
WO2026020004A1 (en) * 2024-07-19 2026-01-22 Gilead Sciences, Inc. Stat6 compounds
WO2026027675A1 (en) 2024-07-31 2026-02-05 Guerra Gonzalez Carmen Triple combination for use in the treatmet of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060742A1 (en) * 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
WO2020198435A1 (en) * 2019-03-26 2020-10-01 The Regents Of The University Of Michigan Small molecule degraders of stat3
US12570679B2 (en) * 2019-03-29 2026-03-10 Regents Of The University Of Michigan STAT3 protein degraders
CN120574283A (zh) * 2019-04-05 2025-09-02 凯麦拉医疗公司 Stat降解剂和其用途

Also Published As

Publication number Publication date
WO2021188696A1 (en) 2021-09-23
AU2021238333A1 (en) 2022-09-29
EP4121055A4 (en) 2024-04-24
IL296334A (en) 2022-11-01
EP4121055A1 (en) 2023-01-25
MX2022011437A (es) 2022-10-03
CN115776891A (zh) 2023-03-10
JP2023518422A (ja) 2023-05-01
US20240016942A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
CA3170503A1 (en) Stat degraders and uses thereof
JP7716554B2 (ja) Stat分解剤およびそれらの使用
CA3161878A1 (en) Irak degraders and uses thereof
CA3162502A1 (en) Smarca degraders and uses thereof
WO2020251971A1 (en) Smarca degraders and uses thereof
WO2020264490A1 (en) Irak degraders and uses thereof
EP4401729A1 (en) Bcl-xl degraders and uses thereof
EP4121043A1 (en) Mdm2 degraders and uses thereof
WO2020010210A1 (en) Mertk degraders and uses thereof
CA3200608A1 (en) Irak degraders and uses thereof
CA3194492A1 (en) Stat degraders and uses thereof
EP4543854A1 (en) Stat degraders and uses thereof
CA3206499A1 (en) Gpr84 antagonists and uses thereof
CN116490069A (zh) Stat降解剂和其用途
CA3240538A1 (en) Oxer1 antagonists and uses thereof
EA048808B1 (ru) Деградаторы stat и их применение
EA051158B1 (ru) Деградаторы stat и их применение

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202